Quality evaluation of diagnosis and treatment guidelines and expert consensus for children with immune thrombocytopenic purpura
- VernacularTitle:儿童免疫性血小板减少性紫癜诊疗指南和专家共识的质量评价
- Author:
Yaping XING
1
;
Ying DING
1
;
Shanshan HAN
1
;
Wenchao XING
2
;
Lu JIA
2
;
Min TONG
2
;
Xiaodan REN
2
Author Information
1. Nephrotic Purpura Diagnosis and Treatment Center，Pediatrics Hospital，the First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450003，China;School of Pediatrics，Henan University of Chinese Medicine，Zhengzhou 450046，China
2. Nephrotic Purpura Diagnosis and Treatment Center，Pediatrics Hospital，the First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450003，China
- Publication Type:Journal Article
- Keywords:
immune thrombocytopenic purpura;
children;
diagnosis and treatment guideline;
expert consensus;
AGREE Ⅱ
- From:
China Pharmacy
2025;36(13):1671-1676
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the quality of diagnosis and treatment guidelines and expert consensuses on childhood immune thrombocytopenic purpura （ITP） published domestically and internationally， in order to provide reference for clinical practice and future guideline/expert consensus development and improvement. METHODS A systematic search was conducted across multiple databases， including PubMed， Cochrane Library， Embase， CNKI， Wanfang data， VIP， CBM； additionally， supplementary searches were carried out on websites such as Medlive， the Chinese Medical Association’s official website， and National Institute for Health and Clinical Excellence in the UK. The retrieval time ranged from the inception to September 2， 2024. Researchers who had undergone systematic training independently evaluated the methodology and report quality included in the guideline/consensus using the Appraisal of Guidelines Research and Evaluation Ⅱ （AGREE Ⅱ） and the Reporting Items for Practice Guidelines in Healthcare （RIGHT）. RESULTS A total of 11 guidelines/consensuses were included. The average scores for the six domains of AGREE Ⅱ tool respectively were “range and purpose” （[ 66.67±17.98）% ]， “participants” [58.33% （13.89%，73.61%）]， “rigor” （[ 41.81±23.85）% ]， “clarity”（[ 69.57±19.35）%]， “applicability” （[ 35.98±17.83）%]， and “independence” [27.08% （0，75.00%）]； out of 11 articles， 9 had a recommendation level of B， 2 had a recommendation level of C， and there were no A-level articles. The average reporting rates of the 7 areas in the RIGHT tool were “basic information” （[ 72.35±12.95）% ]， “background” （[ 54.55±15.40）%]，“ evidence” （[ 36.36±24.81）%]，“ recommended opinions” （[ 53.25±19.20）%]，“ review and quality assurance” [0 （0， 25.00%）]， “funding and conflict of interest statement and management” [12.50%（0，25.00%）]， and other aspects [8.33%（0， 50.00%）]. In addition， there was no statistically significant difference in the AGREE Ⅱ and RIGHT scores between the guidelines and consensuses （P＞0.05）. CONCLUSIONS The overall quality of the guidelines and consensuses included in this study is not high， with a recommended level of B or C. It is recommended that clinical decision-making prioritize referring to the relatively high-quality guideline/consensus among them. The quality of evidence in the existing traditional Chinese medicine guidelines for children with ITP needs to be improved， and there is no integrated guideline/consensus for traditional Chinese and Western medicine. It is recommended to revise or write relevant guideline/consensus according to the requirements of AGREE Ⅱ and RIGHT in various fields to guide clinical practice.
